HB1311
To Amend The Prohibition Of Nonprofit, Tax Exempt, Or Governmentally-funded Hospitals From Holding A Licensed Pharmacy Permit For The Sale Of Drugs At Retail.
Last Action (May 1, 2023): Died in House Committee at Sine Die Adjournment
Sponsors
AI-Generated Summary
House Bill 1311 modifies Arkansas law regarding the ability of nonprofit, tax-exempt, or government-funded hospitals to hold pharmacy permits for the retail sale of drugs. It establishes specific criteria under which these hospitals may operate retail pharmacies on their campuses based on employee headcount: hospitals with fewer than 1,000 employees may operate one location, while those with 1,000 or more employees may operate up to three. The bill also defines 'hospital campus' to clarify where these permits can be utilized. Furthermore, it explicitly allows hospitals that qualify as 'covered entities' under the federal 340B drug pricing program to enter into contracts with outside licensed pharmacies to dispense 340B drugs, provided they conduct a business review and maintain auditable compliance records. These provisions are designed to clarify and expand the circumstances under which such hospitals can participate in retail pharmacy services and 340B drug distribution. The bill maintains existing protections for hospitals that already held pharmacy permits prior to March 28, 1975.
Potential Impact Analysis
Who Might Benefit?
The primary beneficiaries include nonprofit, tax-exempt, and government-funded hospitals, which gain explicit legal authority to operate retail pharmacies on their campuses and contract with outside pharmacies for 340B program participation. Patients served by these hospitals may also benefit from increased access to retail pharmacy services and potentially more affordable medications through the 340B program.
Who Might Suffer?
Privately owned, for-profit retail pharmacies and independent community pharmacists may be negatively impacted by this legislation. These entities could face increased competition from hospital-operated retail pharmacies, which may have different operating models or access to 340B pricing advantages, potentially affecting the market share and revenue of traditional retail pharmacy businesses.
Get Notified
Receive an email when this bill's status changes.